Skip to main content
IQV
NYSE Industrial Applications And Services

IQVIA Q2 Revenue and EPS Top High End of Guidance; Backlog Reaches $34.2B

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$242.94
Mkt Cap
$40.547B
52W Low
$154.5
52W High
$247.718
52W Position info
57% above low
Off High info
1.9% below high
Rel. Volume info
3.0× avg
Market data snapshot near publication time

IQV sits 57% above its 52-week low of $154.5 on elevated volume (3.0× avg).

Summary

IQVIA's Q2 2026 results exceeded the high end of its own guidance, with revenue of $4.37 billion and adjusted EPS of $3.15. The backlog grew to $34.2 billion, and the company repurchased $950 million in shares during the first half.


Key Events · Earnings and Guidance · IQV

  • Q2 Revenue and EPS Beat Guidance

    Revenue of $4.37 billion and adjusted diluted EPS of $3.15 both exceeded the high end of the company's prior guidance, driven by 8.6% growth in Commercial Solutions and 8.8% growth in Research & Development Solutions.

  • Record Backlog of $34.2 Billion

    Research & Development Solutions' contracted backlog reached $34.2 billion as of June 30, 2026, up from $34.0 billion at year-end 2025, with approximately $9.2 billion expected to convert to revenue in the next twelve months.

  • Aggressive Share Repurchases Continue

    IQVIA repurchased 5.5 million shares for $950 million in the first half of 2026, with $2.819 billion remaining under its repurchase authorization following a $2 billion increase approved in May 2026.

  • Restructuring Costs Elevated

    Restructuring costs were $63 million in Q2 and $114 million in H1 2026, as the company continues to streamline operations and reduce overcapacity; actions are expected to continue into 2027.


Analysis · IQV · Industrial Applications And Services

IQVIA delivered Q2 revenue of $4.37 billion and adjusted EPS of $3.15, both above the high end of its prior guidance. Broad-based growth across both segments fueled the beat, with Commercial Solutions up 8.6% and Research & Development Solutions up 8.8%. A record contracted backlog of $34.2 billion signals strong future revenue visibility. Against this backdrop, the company continued its aggressive capital return, repurchasing $950 million in shares during the first half, with $2.8 billion remaining under its authorization. While restructuring costs remain elevated as operations are streamlined, the underlying business momentum is clear.

At the time of this filing, IQV was trading at $242.94 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $40.5B. The 52-week trading range was $154.50 to $247.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IQV - Latest Insights

IQV
Jul 28, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $234.00
Real-time Price: $246.00 info
Change: +$12.00 (+5%) info
Market Cap: $40.547B info
IQV
Jul 28, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $234.00
Real-time Price: $246.00 info
Change: +$12.00 (+5%) info
Market Cap: $40.547B info
IQV
Jun 11, 2026, 4:46 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $181.06
Real-time Price: $246.00 info
Change: +$64.94 (+36%) info
Market Cap: $40.547B info
IQV
Jun 04, 2026, 5:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $186.88
Real-time Price: $246.00 info
Change: +$59.12 (+32%) info
Market Cap: $40.547B info
IQV
Jun 03, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $182.05
Real-time Price: $246.00 info
Change: +$63.95 (+35%) info
Market Cap: $40.547B info